Pharmacogenetics in the Treatment of Cardiovascular Diseases and Its Current Progress Regarding Implementation in the Clinical Routine

There is a special interest in the implementation of pharmacogenetics in clinical practice, although there are some barriers that are preventing this integration. A large part of these pharmacogenetic tests are focused on drugs used in oncology and psychiatry fields and for antiviral drugs. However,...

Full description

Saved in:
Bibliographic Details
Published in:Genes Vol. 10; no. 4; p. 261
Main Authors: Dávila-Fajardo, Cristina Lucía, Díaz-Villamarín, Xando, Antúnez-Rodríguez, Alba, Fernández-Gómez, Ana Estefanía, García-Navas, Paloma, Martínez-González, Luis Javier, Dávila-Fajardo, José Augusto, Barrera, José Cabeza
Format: Journal Article
Language:English
Published: Switzerland MDPI AG 01-04-2019
MDPI
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:There is a special interest in the implementation of pharmacogenetics in clinical practice, although there are some barriers that are preventing this integration. A large part of these pharmacogenetic tests are focused on drugs used in oncology and psychiatry fields and for antiviral drugs. However, the scientific evidence is also high for other drugs used in other medical areas, for example, in cardiology. In this article, we discuss the evidence and guidelines currently available on pharmacogenetics for clopidogrel, warfarin, acenocoumarol, and simvastatin and its implementation in daily clinical practice.
ISSN:2073-4425
2073-4425
DOI:10.3390/genes10040261